“While the evaluation of such a broad proposal with thousands of substances, and many uses, will be challenging, we are ready,” says ECHA director for risk assessment Peter van der Zandt. Prepared by authorities in Denmark, Germany, the Netherlands, Norway and Sweden, the restriction proposal has been handed over to ECHA’s scientific committees.
The EU is exploring two proposed options for restricting more than 10,000 per- and polyfluoroalkyl substances (PFAS) under its Registration, Evaluation, Authorization and Restriction of Chemicals regulation.
The proposal, submitted in January by authorities in Denmark, Germany, the Netherlands, Norway and Sweden, was published on 7...
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
